

Scientific Paper Platform Presentations II—Managed Care/Practice-2

Monday October 20, 2008

3:45 p.m. – 5:45 p.m.

Convention Center: Rooms 110 & 111

Moderator:

David E. Nix, Pharm.D., FCCP
Associate Professor
Pharmacy Practice & Science
Associate Professor Medicine
University of Arizona
Phoenix, Arizona

37. Assessment of the white-coat effect among established hypertensive patients who assert to be well controlled

David A. Bookstaver, Pharm.D., and Christos Hatzigeorgiou, D.O., MPH; Eisenhower Army Medical Center, Ft. Gordon, Georgia

85. Impact of a geriatric palliative care service on suboptimal prescribing

Erin M. Suhrie, Pharm.D., Sherrie Aspinall, Pharm.D., M.Sc., Joseph T. Hanlon, Pharm.D., M.S., Mary Ann Sevick, Sc.D., R.N., Christine Ruby-Scelsi, Pharm.D., and Emily Jaffe, M.D., MBA; VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania; University of Pittsburgh, Pittsburgh, Pennsylvania

180. A cost-effectiveness analysis of computerized clinical decision support systems on bacteremia

Marc H. Scheetz, Pharm.D., M.Sc., Maureen K. Bolon, M.D., M.S., Michael J. Postelnick, R.Ph., BCPS, and Todd A. Lee, Pharm.D., Ph.D.; Northwestern University, Department of Pharmacy Practice, Chicago, Illinois; Northwestern University, Division of Infectious Diseases, Chicago, Illinois; Northwestern Memorial Hospital, Department of Pharmacy, Chicago, Illinois; Institute for Healthcare Studies; Division of General Internal Medicine – Northwestern University Feinberg School of Medicine, Chicago, Illinois

208. A randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking

Larry A. Dent, Pharm.D., BCPS, Kari J. Harris, Ph.D., MPH, and Curtis W. Noonan, Ph.D.; University of Montana, Skaggs School of Pharmacy, Department of Pharmacy Practice, Missoula, Montana; University of Montana, School of Public and Community Health Sciences, Missoula, Montana; University of Montana, Skaggs School of Pharmacy, Department of Biomedical Sciences, Missoula, Montana

250. Development, delivery, and outcomes of a clinical pharmacy service expansion for sexual assault patients in the emergency department

Deborah Larison, Pharm.D., BCPS; Sarasota Memorial Hospital, Sarasota, Florida

Scientific Poster Presentations I

Monday, October 20

11:15 a.m. – 1:15 p.m.

Convention Center: Hall 2D



ENCORE PRESENTATIONS

Abstracts marked with an “E” are Encore Presentations. Encore presentations undergo the same peer review process as all other presentations, but they may have been presented elsewhere or published in abstract form prior to the 2008 Annual Meeting. For Encore Presentations, the abstract title, authors, and original citation (if provided) are published in *Pharmacotherapy*.

FINALISTS IN ABSTRACT AWARDS COMPETITION

Abstracts marked with an “F” are finalists for the Best Poster, Best Resident and Fellow Poster, and Best Student Poster competition. These papers were selected by a special panel of reviewers. Award winner for Best Student Poster will be announced at 1:00 p.m., Monday, October 20, and award winners for Best Resident and Fellow Poster and Best Poster will be announced at 9:45 a.m., Tuesday, October 21, in Hall 2D of the Kentucky International Convention Center.

ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoconomics, and pharmacoepidemiology.

ADR/Drug Interactions

1. Evaluating adverse drug reactions occurring in the medical intensive care unit using three objective instruments for causality assessment.

Sandra L. Kane-Gill, Pharm.D., M.Sc.,¹ Elizabeth A. Forsberg, Pharm.D. Candidate,¹ Cassandra J. Bellamy, Pharm.D.,² Margaret M. Verrico, R.Ph.³; (1) University of Pittsburgh, Pittsburgh, PA; (2) Hospital of the University of Pennsylvania, Philadelphia, PA; (3) University of Pittsburgh Medical Center, Pittsburgh, PA

2. Emerging adverse events with aliskiren: increased blood pressure and angioedema.

Krystal K. Haase, Pharm.D., BCPS, Chris Tawwater, Pharm.D., Eric J. MacLaughlin, Pharm.D., BCPS; Texas Tech University Health Sciences Center, Amarillo, TX

3. Acute kidney injury following exposure to antibiotic-laden bone cement.

Paul Thill, Pharm.D., BCPS; Ferris State University College of Pharmacy, Saginaw, MI

4. Drug interactions in prescriptions for outpatients.

Sukhyang Lee, Pharm.D., Ph.D.,¹ Jung Hwa Lee, M.S.²; (1) Graduate School of Clinical Pharmacy, Sookmyung Women's University, Yong-San Ku, Seoul, South Korea; (2) Graduate School of Clinical Pharmacy, Sookmyung Women's University, Yong-San Ku, Seoul, IA, South Korea

5. Increased risk of significant creatinine kinase elevation with high dose simvastatin compared to moderate dose.

Ryan S. Stolcpart, Pharm.D., Kari L. Olson, Pharm.D., Thomas Delate, Ph.D., Jon R. Rasmussen, Pharm.D., Thomas F. Rehring, M.D., H. Whitton Hollis, Jr., M.D., John A. Merenich, M.D.; Kaiser Permanente Colorado Region, Aurora, CO

6. The valproate related thrombocytopenia.

Ji Young Yun, M.S.,¹ Sukhyang Lee, Pharm.D., Ph.D.²; (1) Graduate School of Clinical Pharmacy, Sookmyung Women's University, Yong-San Ku, Seoul, South Korea; (2) Graduate School of Clinical Pharmacy, Sookmyung Women's University, Yong-San Ku, Seoul, South Korea

Adult Medicine**7. Evaluating the rate of venous thromboembolism (VTE) prophylaxis and percentage of ordered doses administered in medically ill patients.**

Sheila M. Wilhelm, Pharm.D., BCPS,¹ May Chang, Pharm.D., BCPS²; (1) Wayne State University, Detroit, MI; (2) Harper University Hospital, Detroit, MI

8. Evaluation of an argatroban dosing protocol and identification of dose-altering patient characteristics.

Erin L. Schaaf, Pharm.D., Bridget Morse, Pharm.D., Tracy Sprunger, Pharm.D., BCPS; Community Health Network, Indianapolis, IN

9. Ability of the activated partial thromboplastin time versus the antifactor Xa assay to maintain unfractionated heparin within a therapeutic range.

Ryan D. Tabis, Pharm.D., Christopher J. Taylor, Pharm.D., BCPS; Carl T. Hayden VA Medical Center, Phoenix, AZ

Ambulatory Care**10. A method for educating patients and documenting smoking status in an electronic medical record.**

Sarah Shrader, Pharm.D., BCPS, Kelly Ragucci, Pharm.D., FCCP, BCPS, CDE; South Carolina College of Pharmacy – MUSC Campus, Charleston, SC

13. Characteristics of prescription refill requests in a primary care clinic.

Devra K. Dang, Pharm.D., BCPS, CDE,¹ Nina Yen, Pharm.D.,¹ Bruce E. Gould, M.D.,² Keith vom Eigen, M.D., MPH, Ph.D.²; (1) University of Connecticut, Storrs, CT; (2) University of Connecticut School of Medicine, Farmington, CT

14E. Effect of depression on diabetes control and medication adherence in underserved patients.

Devra K. Dang, Pharm.D., BCPS, CDE,¹ Michelle Flynn, Pharm.D.,² Charles Caley, Pharm.D., BCPP,¹ Thomas E. Buckley, R.Ph., MPH,¹ Neil J. Facchinetti, Ph.D.¹; (1) University of Connecticut School of Pharmacy, Storrs, CT; (2) St. Francis Hospital and Medical Center, Hartford, CT

Education/Training**58. Development and assessment of Internet case based multi-disciplinary infectious disease workshops as a learning tool in antimicrobial therapeutics.**

Angela Wilks, Ph.D., Neha U. Sheth, Pharm.D., Shannon Tucker, M.S.; University of Maryland School of Pharmacy, Baltimore, MD

59. Accreditation Council for Graduate Medical Education duty hour compliance and awareness among post-graduate year one pharmacy residents.

Jennifer D. Canady, Pharm.D.,¹ Melanie W. Pound, Pharm.D., BCPS,² Dana Blecke, Pharm.D., BCPS,³ Beth Beasley, Pharm.D.,³ Susan M. Miller, Pharm.D., BCPS⁴; (1) Southern Regional Area Health Education Center and Cape Fear Valley Health System, Fayetteville, NC; (2) Campbell University School of Pharmacy and Cape Fear Valley Health System, Fayetteville, NC; (3) Cape Fear Valley Health System, Fayetteville, NC; (4) University of North Carolina at Chapel Hill School of Pharmacy, Southern Regional AHEC and Cape Fear Valley Health System, Fayetteville, NC

60E. Impact of an introductory leadership course on student leadership beliefs and behaviors.

W. Greg Leader, Pharm.D., Scott A. Baggarly, Ph.D., Mary L. Caldwell, M.Ed., LPC, Laurel L. Andrews, Pharm.D., Lesa W. Lawrence, Ph.D.; University of Louisiana at Monroe College of Pharmacy, Monroe, LA

61. A quizzical approach to innovative experiential teaching.

Amy M. Lugo, Pharm.D., BCPS, BC-ADM,¹ Mina S. Willis, Pharm.D., PA-C,¹ Cynthia J. Boyle, Pharm.D., FAPhA²; (1) National Naval Medical Center, Bethesda, MD; (2) University of Maryland School of Pharmacy, Baltimore, MD

63E. Academic and training requirements in advertisements for pharmacy practice academic positions.

John E. Murphy, Pharm.D., Lisa Hawkey, Pharm.D.; University of Arizona College of Pharmacy, Tucson, AZ

64. Communicating value to the patients we serve – an educational workshop for pharmacy students.

Celia MacDonnell, Pharm.D.,¹ Colleen Moffitt, Pharm.D.²; (1) University of Rhode Island, College of Pharmacy, Kingston, RI; (2) Pfizer, Inc., Wakefield, RI

65. Perceived benefits and negative aspects of postgraduate pharmacy training.

Cara L. Léos, Pharm.D., BCPS, Laura C. Smoot, Pharm.D., BCPS; Auburn University Harrison School of Pharmacy, Auburn University, Auburn, AL

66. Assessment of pharmacy residency's formal training in teaching.

Lauren E. Keyser, Pharm.D., Nancy S. Yunker, Pharm.D., Craig F. Kirkwood, Pharm.D., Jaime R. Robles, Ph.D.; Virginia Commonwealth University Medical Center, Richmond, VA

67. Actively engaging students in the art of peer review.

Wendy I. Brown, Pharm.D., MPAS, PA-C, AE-C; North Dakota State University College of Pharmacy, Nursing and Allied Sciences, Fargo, ND

68. A comparison of patient recall of medication information with and without pharmacist discharge counseling.

Laura Roman, B.S., R.Ph.,¹ Luke Probst, Pharm.D., BCPS,¹ Domenica Pacific, Pharm.D.²; (1) University Hospital, Upstate Medical University, Syracuse, NY; (2) Central New York Psychiatric Center, Marcy, NY

69. Time study of pharmacy faculty in family medicine residency programs.

Sarah M. Westberg, Pharm.D., BCPS, Jean Y. Moon, Pharm.D., Chrystian R. Pereira, Pharm.D., Lisa M. Hlavenka, Student Pharmacist; University of Minnesota College of Pharmacy, Minneapolis, MN

70. Outcomes of an initial preceptor experience for fourth year pharmacy students.

Courtney Krueger, Pharm.D., Kristen L. Goliak, Pharm.D.; University of Illinois at Chicago, College of Pharmacy, Chicago, IL

71. Teaching medication errors: a computer-based approach.

Michael J. Peeters, Pharm.D., BCPS, Gayle L. Kamm, Pharm.D.; University of Toledo College of Pharmacy, Toledo, OH

72. Incorporation of wiki technology into an elective course.

Priti N. Patel, Pharm.D., BCPS, Olga Hilas, Pharm.D., BCPS, CGP; St. John's University, Queens, NY

73. Email vs. face-to-face: faculty and students' perceptions of tone and content.

Pamela A. Foral, Pharm.D., BCPS,¹ Jennifer J. Merkel, Pharm.D. Student,² Paul D. Turner, Ph.D.,¹ Thomas L. Lenz, Pharm.D.,¹ Michael S. Monaghan, Pharm.D.,¹ Ryan W. Walters, M.S.;¹ (1) Creighton University School of Pharmacy and Health Professions, Hixon-Lied Science Building, Omaha, NE; (2) Creighton University School of Pharmacy and Health Professions, Omaha, NE

74. Implementation of a weight-based basal/bolus insulin use strategy improved glycemic control in hospitalized diabetic patients on an internal medicine service.

Stephen J. Schafers, Pharm.D., Eli Deal, Pharm.D., Hemal Gada, M.D., Shivak Sharma, M.D., Donna B. Jeffe, Ph.D., Mitchell G. Scott, Ph.D., Debaroti Borschel, M.D., Melvin Blanchard, M.D., Garry Tobin, M.D.; Barnes-Jewish Hospital at Washington University Medical Center, St. Louis, MO

Herbal/Complementary Medicine**94. The effect of black cherry juice concentrate on serum uric acid in patients with heart failure.**

Anne P. Spencer, Pharm.D., BCPS,¹ Maria Jose Pallares, Pharm.D.,² Adrian Van Bakel, M.D., Ph.D.³; (1) Roper St. Francis Healthcare, Charleston, SC; (2) Miami VA Medical Center, Miami, FL; (3) Medical University of South Carolina, P.O. Box 250132, Charleston, SC

Nutrition**154E. Hyperbilirubinemia is more common in chronic home parenteral nutrition patients with catheter related infections.**

John K. Siepler, Pharm.D., Marianne Opilla, R.N., Thomas Diamantidis, Pharm.D., Reid A. Nishikiawa, Pharm.D., Rod Okamoto, B.S., R.Ph.; Nutrishare, Inc., Elk Grove, CA

Obesity**155. Incidence of vitamin D deficiency after gastric bypass surgery.**

Margaret Malone, Ph.D., FCCP,¹ Sharon Alger-Mayer, M.D.²; (1) Albany College of Pharmacy, Albany, NY; (2) Albany Medical College, Albany, NY

Pediatrics**172. Evaluation of dosage form information provided in pediatric drug trials.**

Mark R. Haase, Pharm.D.,¹ Sherry A. Luedtke, Pharm.D.,¹ Janie Robles, Pharm.D.,² Thomas M. Parker, Pharm.D.,¹ Richard D. Leff, Pharm.D.,³ George P. Giacoia, M.D.⁴; (1) Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX; (2) Texas Tech University Health Sciences Center School of Pharmacy, Lubbock, TX; (3) Texas Tech University Health Sciences Center School of Pharmacy, Building 7, Room 119A, Dallas, TX; (4) National Institute of Child Health and Human Development, Bethesda, MD

Women's Health**222. Knowledge of emergency contraception among health professions students.**

Deborah A. Sturpe, Pharm.D., Jorie A. Glick, Pharm.D., Francoise Pradel, Ph.D., Puckwipa Suwannaprom, M.A., Stuart T. Haines, Pharm.D.; University of Maryland School of Pharmacy, Baltimore, MD

223. Comparison of exogenous intravenous immunoglobulin (IVIG) exposure and endogenous IgG in pregnancy.

Mary H.H. Ensom, Pharm.D., FASHP, FCCP, FCSHP, FCAH,¹ Mai Al-Khatib, B.Sc. (Pharm.), M.Sc. Student,² Lillian S. L. Ting, B.Sc., M.Sc. (Pharm.), Ph.D. Student,² Patricia A. Schultz, R.N., MHA,³ Edwina Houlihan, R.N.,⁴ Mary D. Stephenson, M.D., M.Sc.⁵; (1) University of British Columbia, BC Women's Hospital and Health Centre, Vancouver, BC, Canada; (2) University of British Columbia, Vancouver, BC, Canada; (3) University of Chicago, Chicago, IL; (4) Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada; (5) University of Chicago, University of British Columbia, and Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada

224. Adherence to osteoporosis treatment guidelines in postmenopausal women at two family medicine clinics.

Cary R. Mountjoy, Pharm.D., Sarah Shrader, Pharm.D., BCPS, Kelly Ragucci, Pharm.D., FCCP, BCPS, CDE; South Carolina College of Pharmacy-MUSC Campus, Charleston, SC

CLINICAL PHARMACY FORUM

These abstracts describe the delivery, development, justification, or documentation of innovative clinical pharmacy services; they may be descriptive only and need not contain an evaluative component.

Ambulatory Care**226. Development and implementation of an interdisciplinary mobile wellness clinic for a medically underserved population.**

Monica L. Skomo, B.S., Pharm.D., Holly Lassila, R.Ph., DrPH, Hildegard J. Berdine, B.S., Pharm.D., Christine K. O'Neil, B.S., Pharm.D.; Duquesne University, Pittsburgh, PA

227. Outcomes and perceptions of a pharmacist-managed smoking cessation group clinic.

Ann M. Philbrick, Pharm.D.,¹ Erin N. Newkirk, Pharm.D.,² Karen Farris, Ph.D.,³ Kathleen E. Horner, Pharm.D.,¹ Deanna L. McDanel, Pharm.D.¹; (1) University of Iowa Hospitals and Clinics, Iowa City, IA; (2) Froedtert & the Medical College of Wisconsin, Milwaukee, WI; (3) University of Iowa, Iowa City, IA

228. Antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting.

Melissa J. Snider, Pharm.D., BCPS, Steven Kalbfleisch, M.D., Cynthia Carnes, Pharm.D., Ph.D.; Ohio State University Medical Center, Columbus, OH

229. Patient health outcomes of a pharmacist medication and disease management service in an urban physician office practice using MTM software.

Hildegard J. Berdine, Pharm.D., BCPS, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA

230. Preliminary assessment of asthma quality of care indicators at a multi-disciplinary, primary care clinic for uninsured patients.

Claresta L. Mohrman, Pharm.D., Theresa R. Prosser, Pharm.D.; St. Louis College of Pharmacy, St. Louis, MO

231. Effectiveness of a collaborative lipid clinic developed in an academic heart hospital ambulatory care clinic.

Marguerite Hevezi, Pharm.D., Melissa Snider, Pharm.D., Scott Merryman, M.D., Vasudevan Raghavan, M.D., MBBS, Trisha Jordan, Pharm.D., M.S., Noelle E. Daugherty, Pharm.D.; The Ohio State University Ross Heart Hospital, Columbus, OH

Education/Training**245. Impact of clinical pharmacy services provided through advance practice pharmacy rotations in a rural medical center.**

Kimberly L. Tackett, Pharm.D.,¹ Felix S. Smith, Pharm.D.²; (1) South University, School of Pharmacy, Savannah, GA; (2) Coastal Carolina Medical Center, Hardeeville, SC

246. Descriptive evaluation of a collaborative clinical pharmacy research assistant program for pharmacy students.

Flora G. Estes, Pharm.D.,¹ Lincy S. Lal, Pharm.D., Ph.D.,² Barbara E. Hayes, Ph.D.¹; (1) Texas Southern University College of Pharmacy and Health Sciences, Houston, TX; (2) UT M.D. Anderson Cancer Center, Houston, TX

RESIDENTS AND FELLOWS RESEARCH IN PROGRESS

These papers describe original research by residents and fellows in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoepidemiology, and pharmacogenomics in which the research effort is still on-going.

Adult Medicine**271. Impact of a pharmacist-managed renal dosing protocol in a 317-bed full-service tertiary and acute care referral center.**

Kimball Owens, Pharm.D., C. Dustin Waters, Pharm.D., BCPS; Intermountain Healthcare, McKay-Dee Hospital Center, Ogden, UT

Ambulatory Care**272. A1c outcomes of patients switched from rosiglitazone to insulin.**

Amol D. Joshi, Pharm.D., Thomas J. Worrall, Pharm.D., BCPS; Ralph H. Johnson VA Medical Center, Charleston, SC

Critical Care**275. An evaluation of time-to-initiation of medication admit orders in adverse outcomes of critically ill patients boarded in the emergency department.**

Valerie A. San Luis, Pharm.D., BCPS, Jill M. Hara, Pharm.D., BCPS; Huntington Memorial Hospital, Pasadena, CA

276. Mortality and management of non-ICU patients with severe sepsis

Chris Tawwater, Pharm.D. and Krystal K. Haase, Pharm.D.; Texas Tech University Health Science Center School of Pharmacy, Amarillo, TX

HIV/AIDS**277. AREMIND: a personalized cell phone system to remind for adherence.**

Elke S. Backman, Pharm.D.,¹ Mari-Lynn Drainoni, Ph.D.,² Anela Stanic, Pharm.D.,³ Vikram S. Kumar, M.D.,⁴ Daniel Myung, AB,⁴ Helene Hardy, Pharm.D., M.Sc.,³ Paul R. Skolnik, M.D.,³ Betsy L. Adams, R.N.³; (1) Boston Medical Center, 771 Albany Street, Boston, MA; (2) Boston University School of Public Health, Boston, MA; (3) Boston Medical Center, Boston, MA; (4) Dimagi Inc., Cambridge, MA

Infectious Diseases

278. Susceptibility profile of vaginal isolates of *Candida albicans* prior to and following fluconazole introduction – impact of two decades.

Catharine C. Bulik, Pharm.D.,¹ Jack D. Sobel, M.D.,² Michael D. Nailor, Pharm.D.¹; (1) Detroit Receiving Hospital, Detroit, MI; (2) Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI

279. Clinician response to positive methicillin-resistant *Staphylococcus aureus* (MRSA) surveillance cultures in the intensive care unit (ICU).

Eyerusalem Yemane, Pharm.D.,¹ *Kristi Kuper, Pharm.D., BCPS*²; (1) Suburban Hospital, Bethesda, MD; (2) Cardinal Health CT&S, Houston, TX

280. Use of cytomegalovirus intravenous immune globulin (CMV-IVIG) for the treatment of cytomegalovirus (CMV) in hematopoietic stem cell transplant (HSCT) patients.

Bryan T. Alexander, Pharm.D.,¹ Kristan M. Augustin, Pharm.D., BCOP,¹ Ed Casabar, Pharm.D., BCPS,¹ Lindsay M. Hladnik, Pharm.D., BCOP,¹ Peggy S. McKinnon, Pharm.D., BCPS,¹ Richard M. Reichley, R.Ph.,¹ David J. Ritchie, Pharm.D., FCCP, BCPS,² Peter Westervelt, M.D., Ph.D.,³ Erik R. Dubberke, M.D.³; (1) Barnes-Jewish Hospital, St. Louis, MO; (2) Barnes-Jewish Hospital and St. Louis College of Pharmacy, St. Louis, MO; (3) Washington University School of Medicine, St. Louis, MO

281. Antibiotic use in critically ill patients colonized with multidrug-resistant organisms.

William R. Vincent III, Pharm.D.,¹ Craig A. Martin, Pharm.D.,¹ Aaron M. Cook, Pharm.D.,¹ Jeremy D. Flynn, Pharm.D.,¹ R. Scott Morehead, M.D.,² P. Shane Winstead, Pharm.D.¹; (1) UK HealthCare, Pharmacy Services, University of Kentucky, Lexington, KY; (2) University of Kentucky College of Medicine, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Lexington, KY

282. Assessment of empiric and directed fluconazole and caspofungin usage patterns in patients with candidemia.

Lisa A. Keller, Pharm.D.,¹ Douglas Slain, Pharm.D., BCPS,² Maurice L. Moffett, Ph.D.,² Kimberly B. Blake, Pharm.D., MBA²; (1) West Virginia University Hospitals/West Virginia University School of Pharmacy, Morgantown, WV; (2) West Virginia University School of Pharmacy, Morgantown, WV

283. Assessment of imipenem-cilastatin 500mg q6h, meropenem 500mg q6h, and meropenem 1000mg q8h in adult patients with neutropenic fever.

Heather M. Arnold, Pharm.D.,¹ Peggy S. McKinnon, Pharm.D., BCPS,¹ Kristan M. Augustin, Pharm.D., BCOP,¹ Lindsay M. Hladnik, Pharm.D., BCOP,¹ Ed Casabar, Pharm.D., BCPS,¹ Richard M. Reichley, R.Ph.,¹ Erik R. Dubberke, M.D.,² Peter Westervelt, M.D., Ph.D.,² David J. Ritchie, Pharm.D., BCPS³; (1) Barnes-Jewish Hospital, St. Louis, MO; (2) Washington University School of Medicine, St. Louis, MO; (3) Barnes-Jewish Hospital and St. Louis College of Pharmacy, St. Louis, MO

Nephrology

284. Urinary markers for renal damage in patients undergoing cardiac catheterization receiving contrast dye.

Paula Simoni, Pharm.D.,¹ Allen Cunningham, Pharm.D.,² Jan Simoni, DVM, Ph.D.,³ Audie Kilpatrick, Pharm.D.,² Shalyn Cox, Pharm.D.,² *Charles F. Seifert, Pharm.D.*¹; (1) TTUHSC School of Pharmacy, Lubbock, TX; (2) Covenant Health System, Lubbock, TX; (3) TTUHSC School of Medicine, Lubbock, TX

Oncology

285. Evaluation of safety and efficacy of active hexose correlated compound (AHCC) in combination with liposomal doxorubicin.

Rodney J. Hunter, Pharm.D.,¹ Jing Hong Chen, Ph.D.,¹ Hajime Fugii, Ph.D.,² Koji Wakame, Ph.D.,² Judith A. Smith, Pharm.D., FCCP, BCOP¹; (1) The University of Texas, M.D. Anderson Cancer Center, Houston, TX; (2) Amino Up Chemical Company, Ltd., Sapporo, Japan

286. Evaluating patient characteristics associated with sunitinib adverse events requiring dosing modification.

James Hart, Pharm.D., Brad J. Atkinson, Pharm.D., Tam Bui, Pharm.D., Lianchun Xiao, M.S., Eric Jonasch, M.D.; The University of Texas M.D. Anderson Cancer Center, Houston, TX

Pharmacogenomics/Pharmacogenetics

287. Utilization of UGT1A1 testing prior to irinotecan dosing and administration.

Ebtesam Ahmed, Pharm.D.; UCSF Medical Center, San Francisco, CA

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

288. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a mouse model of pancreatic cancer.

Claire M. Mach, Pharm.D.,¹ Lata Mathew, M.S.,¹ Scott A. Mosley, B.S.,¹ Lawrence Helson, M.D.,² Razelle Kurzrock, M.D.,¹ Judith A. Smith, Pharm.D., BCOP, FCCP, FISOPP¹; (1) UT M.D. Anderson Cancer Center, Houston, TX; (2) SignPath, New York, NY

Public Health

289. National survey of pharmacy services in free medical clinics.

Ann M. Wiesner, Pharm.D.,¹ Douglas T. Steinke, Ph.D.,² William R. Vincent III, Pharm.D.,¹ Kenneth E. Record, Pharm.D.,² Kelly M. Smith, Pharm.D.²; (1) University of Kentucky HealthCare, Lexington, KY; (2) University of Kentucky College of Pharmacy, Lexington, KY

Transplant/Immunology**290. Early detection of persistent post kidney transplant anemia.**

Whitney Y. Hung, Pharm.D.,¹ Shelby L. Corman, Pharm.D., BCPS,¹ Kristine Schonder, Pharm.D.;² (1) University of Pittsburgh Medical Center, Pittsburgh, PA; (2) University of Pittsburgh, Pittsburgh, PA

STUDENT SUBMISSIONS

These papers describe original research by students in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, and pharmacogenomics in which the research effort is still ongoing.

ADR/Drug Interactions**291. Irreversible atorvastatin-induced hearing loss: a case report.**

Cheuk H. Liu, Pharm.D. Candidate,¹ Antonia Alafiris, B.S., Pharm.D., CGP,² Anthony J. Longo, B.S., Pharm.D.,³ Henry Cohen, M.S., Pharm.D., FCCM, BCPP, CGP⁴; (1) Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, Brooklyn, NY; (2) Kingsbrook Jewish Medical Center, Arnold and Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, Brooklyn, NY; (3) Astellas Pharma US, Lynbrook, NY; (4) Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University and Kingsbrook Jewish Medical Center, Brooklyn, NY

Cardiovascular**292. Deferasirox attenuates iron-induced oxidative stress and prevents cardiotoxicity in the iron-overloaded gerbil.**

Rabaa M. Al-Rousan, B.S.Pharm., M.S.,¹ Satyanarayana Paturi, BVSC,² Joseph P. Laurino, Ph.D.,³ Anil K. Gutta, BVSC,² Ravi Kumar Arvapalli, BVSC,² Sunil K. Kakarla, M.S.,¹ Devashish H. Desai, M.S.,¹ Ernest M. Walker, Ph.D.,⁴ Eric R. Blough, Ph.D.⁵; (1) Department of Pharmacology, Physiology and Toxicology, School of Medicine, Marshall University, Huntington, WV; (2) Department of Biological Sciences, School of Medicine, Marshall University, Huntington, WV; (3) Department of Chemistry, University of Tampa, Tampa, FL; (4) Department of Pathology, School of Medicine, Marshall University, Huntington, WV; (5) Department of Biological Sciences, School of Medicine & Cell Differentiation and Development Center, Marshall University, Huntington, WV

293. Assessment of amiodarone monitoring in accordance with North American Society of Pacing and Electrophysiology (NASPE) guidelines at the Veterans Affairs Medical Center, Memphis.

Sarah E. Mizne, B.A., Shannon W. Finks, Pharm.D., Kelly C. Rogers, Pharm.D.; University of Tennessee College of Pharmacy, Memphis, TN

294. Deferasirox attenuates age-associated increases in cardiac and hepatic iron accumulation and improves blood glucose regulation.

Ravi kumar Arvapalli, BVSc,¹ Rabaa M. Al-Rousan, B.S.Pharm., M.S.,² Joseph P. Laurino, Ph.D.,² Sunil K. Kakarla, M.S.,² Anjaiah Katta, M.S.,² Satyanarayana Paturi, M.S.,¹ Anil K. Gutta, M.S.,¹ Lucy Dornon, B.S.,³ Kevin M. Rice, M.S.,² Ernest M. Walker, Ph.D.,⁴ Eric R.

Blough, Ph.D.²; (1) Department of Biological Sciences, Marshall University, Huntington, WV; (2) Department of Pharmacology, Physiology and Toxicology, School of Medicine, Marshall University, Huntington, WV; (3) Department of Cardiology, School of Medicine, Huntington, WV; (4) Department of Pathology, School of Medicine, Marshall University, Huntington, WV

295. Statins and diuretic response in heart failure patients.

Apra Jain, Student, Sheryl L. Chow, Pharm.D., BCPS; Western University of Health Sciences, Pomona, CA

Critical Care**296. Evaluation of bleeding events in surgical patients receiving recombinant human activated protein C.**

Brittany L. Warrick, Pharm.D. Candidate,¹ Rachel C. Stratman, Pharm.D.,² Aaron M. Cook, Pharm.D.,³ P. Shane Winstead, Pharm.D.⁴; (1) University of Kentucky College of Pharmacy, Lexington, KY; (2) UK HealthCare, Lexington, KY; (3) University of Kentucky HealthCare, Lexington, KY; (4) UK HealthCare, Pharmacy Services, University of Kentucky, Lexington, KY

297. Venous thromboembolism risk assessment and prophylaxis in the surgical intensive care unit.

Ann Marie B. Prazak, M.S., Steven E. Pass, Pharm.D., FCCM, BCPS; University of Houston College of Pharmacy, Houston, TX

Drug Information**298. Adapting the formulary decision-making process to evaluate an evidence-based medicine database for use in a college of pharmacy.**

Kathryn M. Ruf, Pharm.D. Candidate, Kelly M. Smith, Pharm.D., BCPS, FASHP; University of Kentucky College of Pharmacy, Lexington, KY

Education/Training**299. Clinical and translational pharmacogenomics: integrating a seminar program with undergraduate pharmacogenomics research.**

Elizabeth L. Sanders, Pharm.D. (2011),¹ Qing Ma, Ph.D.,¹ Daniel A. Brazeau, Ph.D.,¹ Gene D. Morse, Pharm.D., FCCP, BCPS²; (1) University at Buffalo, Buffalo, NY; (2) University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY

Endocrinology**300. Safety of zoledronic acid in the management of osteoporosis.**

Meaghan L. Fox, Pre-Med,¹ Michael P. Kane, Pharm.D.,² Robert S. Busch, M.D.,³ Gary Bakst, M.D.,³ Jill M. Abelseh, M.D.³; (1) Northeastern University, Boston, MA; (2) Albany College of Pharmacy, Albany, NY; (3) The Endocrine Group, LLP, Albany, NY

301. Evaluation of glycemic control in cardiac patients with admission hyperglycemia.

Catherine A. Goulding, H.B.Sc., B.Sc.Pharm., ACPR, Jenny Chiu, B.Sc.Pharm., ACPR, Dave Hallett, M.Sc., Lisa Burry, Pharm.D., Holly Leung, B.Sc.Pharm., Doret Cheng, Pharm.D.; Mount Sinai Hospital, Toronto, ON, Canada

Infectious Diseases**302. Risk factors and clinical features of urinary tract infections in solid organ transplant recipients: a retrospective cohort study.**

Elyn Choa Tan, Pharm.D. Candidate,¹ Rosemary Cross, Pharm.D., BCPS,² Vanthida Huang, Pharm.D., BSPHM¹; (1) Department of Pharmacy Practice, Mercer University College of Pharmacy and Health Sciences, Atlanta, GA; (2) Piedmont Hospital, Atlanta, GA

303F. Impact of the ica operon on biofilm formation and antibiotic susceptibility in *Staphylococcus aureus* (SA) and *epidermidis* (SE).

Peter Poppens, Pharm.D. Candidate,¹ Ryan M. Knier, B.S.,¹ Steven C. Ebert, Pharm.D.,¹ Richard A. Proctor, M.D.,² Warren E. Rose, Pharm.D.¹; (1) University of Wisconsin School of Pharmacy, Madison, WI; (2) University of Wisconsin Department of Medicine, Department of Microbiology and Immunology, Madison, WI

304E. MRSA colonization and infection: a molecular and susceptibility analysis.

Suhani K. Patel, Pharm.D. Candidate,¹ Warren E. Rose, Pharm.D.,¹ Ryan M. Knier, B.S.,¹ Cybele Abad, M.D.,² Linda McKinley, R.N.,² Nasia Safdar, M.D.³; (1) University of Wisconsin School of Pharmacy, Madison, WI; (2) University of Wisconsin Hospital and Clinics, Madison, WI; (3) University of Wisconsin School of Medicine, Madison, WI

305. Guideline adherence of antimicrobial prescribing patterns for lower respiratory tract infections and local resistance pattern correlation.

Heather Barnes, Pharm.D. Candidate, Lauren Stansky, Pharm.D. Candidate, Scott E. Kincaid, Pharm.D.; South University School of Pharmacy, Savannah, GA

306. Staphylococcal spp. biofilm formation in the presence of heparin or tissue plasminogen activator (tPA).

Kevin W. McConeghy, Student,¹ Carol Moore, Pharm.D.,² Kerry L. Laplante, Pharm.D.¹; (1) University of Rhode Island and Veterans Affairs Medical Center, Providence, RI; (2) Henry Ford Hospital, Detroit, MI

308. Levofloxacin: a retrospective evaluation of indication and dosage in urinary tract infections.

Kevin W. McConeghy, Pharm.D. Candidate,¹ Mark Curtis, R.Ph.,¹ Jim Melfi, R.Ph., Pharm.D., Ph.D.²; (1) Roger Williams Medical Center, Providence, RI; (2) Roger Williams Medical Center, Providence, RI

Intravenous Compatibility and Particulate Matter**309. Intravenous infusion combinations and particulate matter.**

Kate Conway, Pharm.D. Candidate, Jimmi Hatton, Pharm.D., FCCP, FCCM, Aaron M. Cook, Pharm.D., BCPS; University of Kentucky, Lexington, KY

Medication Safety**310. Predictors of vancomycin dosage adjustment in hospitalized type-II diabetic patients.**

Cyrus Yazdani, M.S.,¹ Arthur T. Shelton, Pharm.D. Candidate,² Nancy Hanna, Pharm.D.,¹ Roger Bentler, B.S.¹; (1) John C. Lincoln North Mountain Hospital, Phoenix, AZ; (2) Midwestern University College of Pharmacy–Glendale, Phoenix, AZ

Oncology**311. Preliminary evaluation of patient-reported outcomes among patients treated for cancer-related pain at a multidisciplinary symptom management clinic.**

Jennifer L. Hendricks, Pharm.D. Candidate,¹ Jane Pruemer, Pharm.D., BCOP, FASHP,¹ Kyra Whitmer, R.N., Ph.D.,² Linda McCaig, R.N., CNP,² Cheryl Wilhelm, R.N., CNP,² Jennifer Hester, R.N., DPN²; (1) University of Cincinnati, James L. Winkle College of Pharmacy, Cincinnati, OH; (2) The University Hospital-Health Alliance of Greater Cincinnati, Cincinnati, OH

312. Psychological distress as a negative factor for the survival of patients undergoing allogeneic hematopoietic stem cell transplantation. (Encore presented at International Congress of The Pharmaceutical Society of Korea, Jeju, Korea, May 1–3, 2008.)

Ji Eun Park, M.S.,¹ Tae Kyung Kim, B.S.,¹ In Ja Son, Ph.D.,² JungMi Oh, Pharm.D.¹; (1) College of Pharmacy, Seoul National University, Seoul, South Korea; (2) Department of Pharmacy, Seoul National University Hospital, Seoul, South Korea

313. Evaluation of the educational interventions on medical team compliance with NCCN myeloid growth factor guidelines.

Aimee Hammerstrom, B.S.,¹ Jaffar Syed, B.S.,¹ Rodney Hunter, Pharm.D.,² Diane C. Bodurka, M.D.,² Shiney Kurian, APN,² Charlotte Sun, DrPH,² Mark Munsell, M.S.,² Charles Levenback, M.D.,² Judith A. Smith, Pharm.D., BCOP, FCCP, FISOPP²; (1) University of Houston College of Pharmacy, Houston, TX; (2) UT M.D. Anderson Cancer Center, Houston, TX

Pain Management/Analgesia**314. Evaluation of pain medication prescribing practices in an outpatient clinic.**

Laura A. Prather, Pharm.D.,¹ Patricia Wigle, Pharm.D.,² Jeff J. Guo, Ph.D.²; (1) University of Cincinnati, Cincinnati, OH; (2) University of Cincinnati, 304 Wherry Hall, Cincinnati, OH

Pharmacoeconomics/Outcomes**315. Inpatient resource utilization associated with bipolar disorder in children and adolescents.**

Edmund Berry, M.S., Finance, M.S., Quantitative, A, Pamela C. Heaton, Ph.D.; University of Cincinnati, Cincinnati, OH

Pharmacogenomics/Pharmacogenetics

316. Clinical and genetic risk factors of new-onset post transplant diabetes mellitus in adult Hispanic renal transplant recipients.

Mai T. Vuong, Pharm.D.,¹ Jae-Wook Yang, Ph.D., Pharm.D.,² Vera Pravica, M.D., Ph.D.,³ Ian V. Hutchinson, Ph.D., D.Sc.,⁴ Tariq Shah, M.D.,⁵ David Min, Pharm.D.¹; (1) Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, CA; (2) USC/National Institute of Transplantation, Los Angeles, CA; (3) USC/National Institute of Transplantation, Los Angeles, CA; (4) USC School of Pharmacy, Los Angeles, CA; (5) St. Vincent Medical Center and National Institute of Transplantation, Los Angeles, CA

317. Effect of genetic polymorphisms of MDR-1 and CYP3A5 on tacrolimus pharmacokinetics after renal transplantation.

Yoo Jin Moon, B.S.,¹ Yang Jin Park, M.D.,² Shi-hwa Kim, B.S.,² Hye-Jin Hong, B.S.,² Yu Jin Joeng, B.S.,² Eun Hee Ji, M.S.,¹ In Ja Son, Ph.D.,³ Seung-Kee Min, M.D.,² Jongwon Ha, M.D.,² Sang Joon Kim, M.D.,² JungMi Oh, Pharm.D.¹; (1) College of Pharmacy, Seoul National University, Seoul, South Korea; (2) Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea; (3) Department of Pharmacy, Seoul National University Hospital, Seoul, South Korea

318F. TPMT pharmacogenetics and the risk for secondary brain tumors after antileukemic therapy.

Jonathan Lee, Pharm.D., candidate, Ph.D., Allen Sills, M.D., Anand Kulkarni, M.D., Cameila Johns, M.D., Terreia Jones, Pharm.D.; University of Tennessee Health Science Center, Memphis, TN

319. High-dose atorvastatin lowers blood pressure in a CXCL5 genotype-dependent manner.

Gregory J. Welder, A.A.,¹ Richard S. Schofield, M.D.,² Issam Zineh, Pharm.D.¹; (1) University of Florida College of Pharmacy Department of Pharmacy Practice and Center for Pharmacogenomics, Gainesville, FL; (2) Division of Cardiovascular Medicine, University of Florida College of Medicine, and Department of Veterans Affairs Medical Center, Gainesville, FL

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

320F. Alterations in the expression of intestinal transporters and metabolic enzymes in cultured intestinal cells treated with green tea extract.

Shu Zhang, B.S.,¹ Xiaomei Zheng, M.S.,¹ Lingling An, M.S.,² Andrea Rau, M.S.,² Paul Livermore Auer, M.S.,² R.W. Doerge, Ph.D.,² David R. Foster, Pharm.D.¹; (1) Purdue University, Department of Pharmacy Practice, Indianapolis, IN; (2) Purdue University, Department of Statistics, West Lafayette, IN

321. Mycophenolic acid pharmacodynamics in nonmyeloablative unrelated donor hematopoietic cell transplant patients.

Jennifer A. Knutson, Pharm.D. Candidate,¹ Brenda M. Sandmaier, M.D.,² Barry E. Storer, Ph.D.,² David G. Maloney, M.D.,² Rainer F. Storb, M.D.,² Meagan J. Bemer, M.S.,² Jeannine S. McCune, Pharm.D.¹; (1) University of Washington, Seattle, WA; (2) Fred Hutchinson Cancer Research Center, Seattle, WA

322. Ethinylestradiol – mediated regulation of hepatic cytochrome P450 enzymes in rats.

Su-Young Choi, B.S., Hyunyoung Jeong, Pharm.D., Ph.D.; University of Illinois at Chicago, Chicago, IL

323. Mycophenolic acid pharmacodynamics in nonmyeloablative, HLA-matched related hematopoietic cell transplant (HCT) recipients.

Cara L. McDermott, B.A.,¹ Brenda M. Sandmaier, M.D.,² Barry E. Storer, Ph.D.,² David G. Maloney, M.D.,² Rainer F. Storb, M.D.,² Meagan J. Bemer, M.S.,² Jeannine S. McCune, Pharm.D.¹; (1) University of Washington School of Pharmacy, Seattle, WA; (2) Fred Hutchinson Cancer Research Center, Seattle, WA

324F. Atorvastatin regulates global inflammatory and anti-inflammatory gene expression in human endothelial cells.

Gregory J. Welder, A.A., Issam Zineh, Pharm.D.; University of Florida College of Pharmacy Department of Pharmacy Practice and Center for Pharmacogenomics, Gainesville, FL

Pulmonary

325. Evaluating the risk of right-sided heart failure or edema with ambrisentan compared with bosentan.

David M. Crowther, B.S., Physiology,¹ Krystal L. Moorman, Pharm.D.²; (1) University of Southern Nevada, Midvale, UT; (2) Intermountain Medical Center, Murray, UT

326. Tissue plasminogen activator: anti-inflammatory agent via modulation of Rac2.

Christine Kim, Pharm.D., 2010, Joshua E. Pitzer, M.S., Regine L. Caruthers, Pharm.D., Kathleen A. Stringer, Pharm.D.; University of Michigan College of Pharmacy, Ann Arbor, MI

Substance Abuse/Toxicology

327. Interaction of ibogaine analogs with the nicotinic acetylcholine receptor.

Mary E. Ghafoori, Pharm.D. Candidate,¹ Krzysztof Jozwiak, Ph.D.,² Irving W. Wainer, Ph.D.,² Hugo R. Arias, Ph.D.¹; (1) Department of Pharmaceutical Sciences, Midwestern University College of Pharmacy–Glendale, Glendale, AZ; (2) Gerontology Research Center, NIA-NIH, Baltimore, MD

328. Interaction of novel ibogaine analogs with the human $\alpha 3\beta 4$ nicotinic receptor.

Mary E. Ghafoori, Pharm.D. Candidate,¹ Dominik Feuerbach, Ph.D.,² Hugo R. Arias, Ph.D.¹; (1) Department of Pharmaceutical Sciences, Midwestern University College of Pharmacy–Glendale, Glendale, AZ; (2) Novartis Institutes for BioMedical Research, Basel, Switzerland

329. Unknown medication ingestions in children less than 6 years: an 8-year retrospective database analysis.

Kristen E. Hillebrand, Pharm.D., B.A.,¹ Jan Scaglione, Pharm.D., DABAT,² Alysha Behrman, BSN, RNII, CSPI, OCPS II, CARN,² Sheila Goertemoeller, R.Ph., CSPI, OCPS II²; (1) Cincinnati Children's Hospital Drug and Poison Information Center and University of Cincinnati College of Pharmacy, Cincinnati, OH; (2) Cincinnati Children's Hospital Drug and Poison Information Center, Cincinnati, OH

330. Implementation of a student pharmacist tobacco cessation program.

Anthony M. Tardi, Pharm.D. Candidate, Roy A. LaBarge, Pharm.D. Candidate, Ashley M. Fulton, Pharm.D. Candidate, Nancy S. Maylath, HSD, Alan P. Farkas, M.S., R.Ph., Karen S. Hudmon, DrPH, Alan J. Zillich, Pharm.D.; Purdue University, West Lafayette, IN

Transplant/Immunology**331. 3-year outcomes of basiliximab induction in African American kidney transplant recipients of deceased donor transplants.**

Kimberly A. DuBrueler, Pharm.D. Candidate, Nicole Sifontis, Pharm.D., BCPS; Temple University School of Pharmacy, Philadelphia, PA

332. Efficacy and safety of low-dose valganciclovir in cytomegalovirus prophylaxis in kidney transplantation following alemtuzumab induction.

Shannon M. McLaughlin, Pharm. Candidate,¹ Kristine S. Schonder, Pharm.D.²; (1) University of Pittsburgh School of Pharmacy, Canonsburg, PA; (2) University of Pittsburgh School of Pharmacy, Pittsburgh, PA

333. Thymoglobulin® induced antibody mediated rejection in a living related kidney transplant patient.

Anna Kipervasser, Pharm.D. Candidate, Bethann Feist, Pharm.D. Candidate, Patrick J. McDonnell, Jr., Pharm.D., Nicole M. Sifontis, Pharm.D., BCPS; Temple University School of Pharmacy, Philadelphia, PA

Scientific Paper Platform Presentations III – Special Populations/Genetic Variations

Tuesday, October 21, 2008

1:15 p.m. – 3:15 p.m.

Convention Center: Rooms 106 & 107

Moderator:

Mark S. Shaefer, Pharm.D.

Group Director

HIV Clinical Research

Infectious Disease Medicine Development Center

GlaxoSmithKline

Research Triangle Park, North Carolina

18. Circulating aldosterone and mineralocorticoid receptor genotype are predictive of potassium response to spironolactone in heart failure

Larisa H. Cavallari, Pharm.D., Vicki L. Groo, Pharm.D., Marlos A. Viana, Ph.D., Yang Dai, Ph.D., Shitalben R. Patel, M.S., and Thomas D. Stamos, M.D.; University of Illinois at Chicago, Chicago, Illinois

192. Vitamin K epoxide reductase genotype is associated with warfarin dose requirements in Hispanics

Larisa H. Cavallari, Pharm.D., Kathryn M. Momary, Pharm.D., Nancy L. Shapiro, Pharm.D., Edith A. Nutescu, Pharm.D., Shitalben R. Patel, M.S., and Marlos A.G. Viana, Ph.D.; University of Illinois at Chicago, Chicago, Illinois

196. Association of CYP3A5 and VEGF gene polymorphisms with hypertensive nephropathy

Jae-Wook Yang, Ph.D., Pharm.D., Ian V. Hutchinson, Ph.D., D.Sc., Vera Pravica, M.D., Ph.D., Tariq Shah, M.D., Deborah Maurer, R.N., MBA, and David I. Min, Pharm.D.; Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, California; USC School of Pharmacy, Los Angeles, California; USC/National Institute of Transplantation, Los Angeles, California; St. Vincent Medical Center and National Institute of Transplantation, Los Angeles, California; St. Vincent Medical Center, Los Angeles, California

198. Influence of serotonin transporter genotype on aspirin response

Kathryn M. Momary, Pharm.D., BCPS, Jeffrey R. Bishop, Pharm.D., M.S., Nancy L. Shapiro, Pharm.D., Edith Nutescu, Pharm.D., Larry Brace, Ph.D., Stacy Shord, Pharm.D., BCOP, Cathy M. Helgason, M.D., and Larisa H. Cavallari, Pharm.D.; University of Illinois at Chicago College of Pharmacy, Chicago, Illinois; University of Illinois at Chicago College of Medicine, Chicago, Illinois